EFM
E Fund Management Portfolio holdings
AUM
$2.1B
1-Year Return
23.31%
This Quarter Return
+1.57%
1 Year Return
+23.31%
3 Year Return
+155.42%
5 Year Return
–
10 Year Return
–
AUM
$1.61B
AUM Growth
+$36.4M
(+2.3%)
Cap. Flow
+$105M
Cap. Flow
% of AUM
6.47%
Top 10 Holdings %
Top 10 Hldgs %
61.46%
Holding
387
New
81
Increased
131
Reduced
147
Closed
19
Top Buys
| 1 |
ASE Group
ASX
|
$25.3M |
| 2 |
Microsoft
MSFT
|
$12.9M |
| 3 |
NVIDIA
NVDA
|
$11.9M |
| 4 |
Apple
AAPL
|
$9.18M |
| 5 |
Amazon
AMZN
|
$7.47M |
Top Sells
| 1 |
Sea Limited
SE
|
$24.3M |
| 2 |
Advanced Micro Devices
AMD
|
$16.8M |
| 3 |
TSMC
TSM
|
$8M |
| 4 |
Weibo
WB
|
$2.43M |
| 5 |
Pinduoduo
PDD
|
$2.4M |
Sector Composition
| 1 | Consumer Discretionary | 40.2% |
| 2 | Technology | 29.79% |
| 3 | Communication Services | 9.9% |
| 4 | Healthcare | 5.71% |
| 5 | Real Estate | 4.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
226
CoStar Group
CSGP
$37.7B
| $388K | 0.02% |
4,019
-48
| -1% | -$4.64K |
|
227
Recursion Pharmaceuticals
RXRX
$1.97B
| $386K | 0.02% |
38,727
-15,367
| -28% | -$153K |
|
228
Nuvalent
NUVL
$5.74B
| $386K | 0.02% |
5,136
-1,662
| -24% | -$125K |
|
229
Arcutis Biotherapeutics
ARQT
$1.94B
| $385K | 0.02% |
+38,866
| New | +$385K |
|
230
Beam Therapeutics
BEAM
$1.88B
| $382K | 0.02% |
11,547
-6,627
| -36% | -$219K |
|
231
Novavax
NVAX
$1.27B
| $380K | 0.02% |
79,514
-7,044
| -8% | -$33.7K |
|
232
Celldex Therapeutics
CLDX
$1.51B
| $380K | 0.02% |
9,046
+1,097
| +14% | +$46K |
|
|
233
Weibo
WB
$2.83B
| $377K | 0.02% |
41,516
-267,620
| -87% | -$2.43M |
|
234
BioCryst Pharmaceuticals
BCRX
$1.74B
| $377K | 0.02% |
74,180
+22,863
| +45% | +$116K |
|
235
Geron
GERN
$880M
| $376K | 0.02% |
113,941
+24,308
| +27% | +$80.2K |
|
236
TE Connectivity
TEL
$61.6B
| $375K | 0.02% |
2,581
-41
| -2% | -$5.96K |
|
237
Pultegroup
PHM
$27.2B
| $374K | 0.02% |
+3,104
| New | +$374K |
|
238
CRISPR Therapeutics
CRSP
$4.8B
| $374K | 0.02% |
5,491
-3,969
| -42% | -$271K |
|
239
Keros Therapeutics
KROS
$632M
| $374K | 0.02% |
+5,648
| New | +$374K |
|
240
Arrowhead Research
ARWR
$3.87B
| $371K | 0.02% |
12,956
-6,575
| -34% | -$188K |
|
241
Elevance Health
ELV
$69.4B
| $370K | 0.02% |
713
+93
| +15% | +$48.2K |
|
242
Exelon
EXC
$43.8B
| $369K | 0.02% |
9,831
-82
| -0.8% | -$3.08K |
|
|
MORF
243
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $367K | 0.02% |
10,434
-454
| -4% | -$16K |
|
244
Catalyst Pharmaceutical
CPRX
$2.42B
| $367K | 0.02% |
23,003
+4,090
| +22% | +$65.2K |
|
245
Ardelyx
ARDX
$1.58B
| $364K | 0.02% |
49,868
-23,717
| -32% | -$173K |
|
246
Stryker
SYK
$151B
| $363K | 0.02% |
1,014
+57
| +6% | +$20.4K |
|
247
Medtronic
MDT
$119B
| $359K | 0.02% |
4,124
+507
| +14% | +$44.2K |
|
248
Vera Therapeutics
VERA
$1.4B
| $356K | 0.02% |
+8,260
| New | +$356K |
|
249
Prothena Corp
PRTA
$442M
| $355K | 0.02% |
14,340
+3,244
| +29% | +$80.4K |
|
250
Akero Therapeutics
AKRO
$3.52B
| $351K | 0.02% |
13,899
-10,273
| -42% | -$259K |
|